KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 159 filers reported holding KITE PHARMA INC in Q2 2015. The put-call ratio across all filers is 2.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $17,470,339,000 | -39.9% | 97,160 | -65.4% | 0.02% | -42.9% |
| Q2 2017 | $29,074,252,000 | +18.5% | 280,450 | -10.3% | 0.03% | +12.0% |
| Q1 2017 | $24,533,463,000 | +135279.4% | 312,568 | -22.7% | 0.02% | +25.0% |
| Q4 2016 | $18,122,000 | -17.4% | 404,137 | +2.9% | 0.02% | -16.7% |
| Q3 2016 | $21,944,000 | +7.8% | 392,846 | -3.5% | 0.02% | +4.3% |
| Q2 2016 | $20,361,000 | +17.5% | 407,236 | +7.9% | 0.02% | +15.0% |
| Q1 2016 | $17,334,000 | -23.4% | 377,578 | +2.8% | 0.02% | -23.1% |
| Q4 2015 | $22,639,000 | -3.3% | 367,411 | -12.6% | 0.03% | 0.0% |
| Q3 2015 | $23,419,000 | -9.1% | 420,617 | -0.4% | 0.03% | +4.0% |
| Q2 2015 | $25,753,000 | +35.8% | 422,399 | +28.5% | 0.02% | +38.9% |
| Q1 2015 | $18,965,000 | +3438.2% | 328,800 | +3435.5% | 0.02% | +1700.0% |
| Q4 2014 | $536,000 | -75.1% | 9,300 | -87.7% | 0.00% | -50.0% |
| Q3 2014 | $2,155,000 | – | 75,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |